STOCKWATCH: EU conditional approvals – what gives?

The adjectives used to describe PTC Therapeutics' conditional European approval for its drug Translarna (ataluren) for Duchenne muscular dystrophy ranged from 'surprise' to 'historic' and helped to bolster PTC's share price by 30% by the close of the day of the announcement (scripintelligence.com, 23 May 2014). PTC's regulatory success was certainly unexpected as it followed a previous rejection by CHMP which cited limited evidence of Translarna's efficacy (scripintelligence.com, 24 January 2014).

The adjectives used to describe PTC Therapeutics' conditional European approval for its drug Translarna (ataluren) for Duchenne muscular dystrophy ranged from 'surprise' to 'historic' and helped to bolster PTC's share price by 30% by the close of the day of the announcement (scripintelligence.com, 23 May 2014). PTC's regulatory success was certainly unexpected as it followed a previous rejection by CHMP which cited limited evidence of Translarna's efficacy (scripintelligence.com, 24 January 2014).

However, the recent track record of European drug approvals, especially conditional approvals such as that of PTC's Translarna, may be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

More from Therapy Areas

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.